Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma and hematological malignancies. This drug was developed by Seattle Genetics, Inc.
| Property | Value |
|---|---|
| dbpedia-owl:abstract |
|
| dbpedia-owl:atcPrefix |
|
| dbpedia-owl:casNumber |
|
| dbpprop:atcPrefix |
|
| dbpprop:c |
|
| dbpprop:casNumber |
|
| dbpprop:h |
|
| dbpprop:mabType |
|
| dbpprop:molecularWeight |
|
| dbpprop:n |
|
| dbpprop:o |
|
| dbpprop:s |
|
| dbpprop:source |
|
| dbpprop:target | |
| dbpprop:type |
|
| dbpprop:unii |
|
| dbpprop:verifiedfields |
|
| dbpprop:verifiedrevid |
|
| dbpprop:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| foaf:page | |
| is owl:sameAs of | |
| is foaf:primaryTopic of |



